Serna Bio
Serna Bio, formerly Ladder Therapeutics (LTX), is a biotech company specializing in the development of novel therapeutics targeting the transcriptome for diseases with high unmet medical needs.
Company History
Serna Bio, formerly known as Ladder Therapeutics (LTX), operates in the healthcare industry with a focus on therapeutics. It was part of Y Combinator's W21 batch. The company is in the early stage of development and aims to create novel therapeutics for diseases that have a high unmet medical need. The company targets the transcriptome, contributing to the field of biotech and drug discovery.
Company Locations
Serna Bio has established operations in Ontario, CA, USA, and London, England, United Kingdom. Additionally, the company offers remote positions, allowing for a flexible working environment. It is active in several regions, including the United States of America, United Kingdom, America / Canada, Europe, and offers fully remote opportunities.
Industry and Sub-Industry
Serna Bio is situated within the healthcare industry, specifically focusing on the sub-industry of therapeutics. The company's efforts are directed towards developing novel therapeutics by targeting the transcriptome. This focus places Serna Bio at the intersection of biotech and drug discovery, contributing to advancements in healthcare solutions for global diseases.
Team and Structure
The team at Serna Bio is currently small, consisting of only 2 members. Despite its modest size, the company is making strides in the healthcare sector by participating in accelerator programs such as Y Combinator's W21 batch. The small team allows for agile and flexible operations, which is complemented by their remote working capabilities.
Y Combinator Involvement
Serna Bio was part of the Y Combinator W21 batch. This affiliation with Y Combinator, a prominent startup accelerator, highlights the company's innovative approach and early-stage potential. Participation in this program provides Serna Bio with networking opportunities, mentorship, and resources that are crucial for the development and growth of their novel therapeutics.